SAGE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SAGE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Sage Therapeutics's cash to debt ratio for the quarter that ended in Dec. 2024 was 42.62.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Sage Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Dec. 2024.
The historical rank and industry rank for Sage Therapeutics's Cash-to-Debt or its related term are showing as below:
During the past 13 years, Sage Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 27.19. And the median was 125.35.
The historical data trend for Sage Therapeutics's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Sage Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Cash-to-Debt | Get a 7-Day Free Trial |
![]() |
![]() |
74.72 | 94.53 | 104.87 | 145.83 | 42.62 |
Sage Therapeutics Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Cash-to-Debt | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
145.83 | 216.88 | 458.39 | 55.40 | 42.62 |
For the Biotechnology subindustry, Sage Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Sage Therapeutics's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Sage Therapeutics's Cash-to-Debt falls into.
This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.
Sage Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2024 is calculated as:
Cash to Debt Ratio | = | Cash, Cash Equivalents, Marketable Securities | / | Total Debt | ||
= | Cash, Cash Equivalents, Marketable Securities | / | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | |
= | 504.418 | / | (1.318 | + | 10.518) | |
= | 42.62 |
Sage Therapeutics's Cash to Debt Ratio for the quarter that ended in Dec. 2024 is calculated as:
Cash to Debt Ratio | = | Cash, Cash Equivalents, Marketable Securities | / | Total Debt | ||
= | Cash, Cash Equivalents, Marketable Securities | / | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | |
= | 504.418 | / | (1.318 | + | 10.518) | |
= | 42.62 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sage Therapeutics (NAS:SAGE) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Thank you for viewing the detailed overview of Sage Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.
Elizabeth Barrett | director | C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142 |
Jessica Federer | director | C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142 |
Jeffrey M Jonas | director, officer: See Remarks | ROBERTS SHERIDAN & KOTEL, 12 EAST 49TH STREET 30TH FL, NEW YORK NY 10017 |
Barry E Greene | director | C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502 |
Laura Gault | officer: Chief Medical Officer | C/O SAGE THERAPEUTICS, INC., 245 FIRST STREET, SUITE 16, CAMBRIDGE MA 02142 |
George Golumbeski | director | C/O CELGENE CORP., 86 MORRIS AVENUE, SUMMIT NJ 07901 |
Christopher Benecchi | officer: Chief Commercial Officer | C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142 |
James M Frates | director | 88 SIDNEY ST, CAMBRIDGE MA 021394136 |
Biogen Inc. | 10 percent owner | 225 BINNEY STREET, CAMBRIDGE MA 02142 |
Biogen Ma Inc. | 10 percent owner | 225 BINNEY STREET, CAMBRIDGE MA 02142 |
Albert Robichaud | officer: Chief Scientific Officer | 215 FIRST STREET, CAMBRIDGE MA 02142 |
Michael Cloonan | officer: Chief Business Officer | C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142 |
Anne Marie Cook | officer: General Counsel | 101 MAIN STREET, SUITE 1850, CAMBRIDGE MA 02142 |
Steven M Paul | director | C/O ELI LITTY & CO, LIIY CORPORATE CENTER DC 1093, INDIANAPOLIS IN 46285 |
Kimi Iguchi | officer: See Remarks | 100 FOXBOROUGH BOULEVARD, SUITE 240, FOXBOROUGH MA 02035 |
From GuruFocus
By Business Wire • 02-11-2025
By GuruFocus News • 02-12-2025
By GuruFocus News • 02-12-2025
By GuruFocus News • 10-30-2024
By GuruFocus News • 01-31-2025
By Business Wire • 01-08-2025
By Business Wire • 11-26-2024
By Business Wire • 01-28-2025
By Business Wire • 03-17-2025
By GuruFocus News • 03-07-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.